PM226

PM226 is a selective cannabinoid CB2R agonist (Ki (CB2R) =13 nM; EC50 (CB2R) =39 nM; Ki (CB1R) >40 μM; ) with neuroprotective properties in vitro and vivo[1].

Product Specifications

CAS Number

[1949726-13-9]

UNSPSC

12352005

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pm226.html

Solubility

10 mM in DMSO

Smiles

CC1(C)OC2=CC(C(C)(C)CCCCCC)=CC(OC)=C2C3=C1C=NO3

Molecular Formula

C22H31NO3

Molecular Weight

357.49

References & Citations

[1]Gemma Navarro, et al. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Front Neurosci. 2016 Sep 13;10:406.|[2]M Gómez-Cañas, et al. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-215.